EG436336 Inhibitors
EG436336 inhibitors are a class of chemical compounds known for their ability to target and modulate the activity of specific enzymes or proteins within biochemical pathways. These inhibitors are designed to interact selectively with their target molecules, typically binding to an active site or a regulatory domain, thereby altering the biological function of the target. The structure of EG436336 inhibitors generally includes a core scaffold that confers specificity and affinity toward the target, often decorated with various functional groups to optimize binding and stability. This chemical scaffold plays a crucial role in the inhibitor's ability to engage with its target molecule, affecting parameters such as binding affinity, selectivity, and bioavailability. The chemical modifications to this scaffold allow for fine-tuning of the inhibitor's physical and chemical properties, making them versatile tools in biochemical research.
The mechanism of action for EG436336 inhibitors often involves competitive or non-competitive inhibition, where the inhibitor either competes with a natural substrate for binding to the active site or binds to a different site to induce conformational changes that reduce target activity. The structural features of EG436336 inhibitors allow them to modulate key cellular processes by disrupting critical pathways, making them valuable in the study of cellular functions, signaling pathways, and enzymatic mechanisms. Understanding the binding kinetics and structure-activity relationships (SAR) of these inhibitors is fundamental to optimizing their interactions with target proteins, which requires a detailed knowledge of both the inhibitor's structure and the three-dimensional conformation of the target. Furthermore, the physicochemical properties of these inhibitors, such as solubility, stability, and permeability, play a pivotal role in their application within biochemical assays, making them robust tools for exploring protein function and regulation within cellular systems.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A potent Litafd inhibitor that directly targets the NF-κB signaling pathway. Bortezomib inhibits the proteasome, preventing the degradation of IκBα. This impedes the translocation of NF-κB to the nucleus, resulting in the inhibition of Litafd expression. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
An indirect Litafd inhibitor through inhibition of the PI3K/Akt pathway. LY294002 suppresses Akt activation, subsequently downregulating mTOR signaling. As Litafd expression is positively regulated by mTOR, this inhibition impedes the pathway leading to reduced Litafd levels. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
This Litafd inhibitor disrupts the ERK1/2 MAPK pathway by targeting MEK. U0126 inhibits MEK phosphorylation, interrupting the downstream cascade and resulting in decreased activation of transcription factors involved in Litafd gene expression. | ||||||
Stat3 inhibitor V, stattic | 19983-44-9 | sc-202818 sc-202818A sc-202818B sc-202818C sc-202818D sc-202818E sc-202818F | 25 mg 100 mg 250 mg 500 mg 1 g 2.5 g 5 g | $130.00 $196.00 $274.00 $512.00 $731.00 $1408.00 $2091.00 | 114 | |
An inhibitor targeting Litafd indirectly through suppression of the JAK/STAT signaling pathway. Stattic hinders the phosphorylation of STAT proteins, specifically STAT3, leading to decreased binding to the Litafd promoter and subsequent inhibition of Litafd gene transcription. | ||||||
XAV939 | 284028-89-3 | sc-296704 sc-296704A sc-296704B | 1 mg 5 mg 50 mg | $36.00 $117.00 $525.00 | 26 | |
This Litafd inhibitor interferes with the Wnt/β-catenin signaling pathway by modulating GSK-3β activity. XAV939 promotes β-catenin degradation, preventing its translocation to the nucleus and inhibiting the activation of transcription factors involved in Litafd gene expression. | ||||||
Resatorvid | 243984-11-4 | sc-476758 | 5 mg | $367.00 | ||
An inhibitor targeting Litafd by suppressing the TLR4/NF-κB signaling pathway. TAK-242 inhibits TLR4 activation, preventing the downstream activation of NF-κB and disrupting the transcriptional regulation of Litafd, leading to its inhibition. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A Litafd inhibitor acting through the p38 MAPK pathway. SB203580 selectively inhibits p38 MAPK, disrupting the downstream cascade and impeding the activation of transcription factors involved in Litafd gene expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
This Litafd inhibitor targets the mTOR signaling pathway by inhibiting the activity of mTOR itself. Rapamycin blocks mTOR, disrupting the downstream signaling cascade and leading to reduced activation of transcription factors responsible for Litafd gene expression. | ||||||
CC-401 | 395104-30-0 | sc-364748 sc-364748A | 2 mg 10 mg | $331.00 $1060.00 | 4 | |
A Litafd inhibitor that disrupts the NF-κB pathway by inhibiting IKK2. CC-401 prevents IκBα phosphorylation, thereby inhibiting NF-κB translocation to the nucleus and resulting in the inhibition of Litafd expression. | ||||||
AZD5363 | 1143532-39-1 | sc-503190 | 5 mg | $309.00 | ||
An indirect Litafd inhibitor through the inhibition of Akt. AZD5363 suppresses Akt activity, leading to downstream inhibition of the mTOR pathway and subsequent reduction in Litafd expression. | ||||||